Intercept Pharmaceuticals (ICPT) Receives Accelerated Approval From FDA for Ocaliva

Shares of Intercept Pharmaceuticals (ICPT) were up +9.23 or +6.51 percent to $151.00 per share in Tuesday's premarket after the company was granted accelerated approval by the FDA for Ocaliva or obeticholic acid, in combination with ursodeoxycholic or UDCA for treating primary biliary cholangitis or PBC. Intercept Pharmaceutical stock closed at $141.77, up +4.04 or ... READ MORE Read the rest of Intercept Pharmaceuticals (ICPT) Receives Accelerated Approval From FDA for Ocaliva at InvestorGuide.com .